Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Ronald Kurlander

Psychiatry Pompano Beach, FL Medical Doctor

NPI 1912010075 CMS profile 86548

1 W Sample Rd, Suite 205, Pompano Beach, FL 33064

Open in the dashboard

General payments

$11,918

446 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Ronald Kurlander of Pompano Beach, FL is reported in the CMS Open Payments database as having received $11,918 across 446 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $924 24
2023 General $2,284 68
2022 General $2,163 67
2021 General $1,813 90
2020 General $1,544 85
2019 General $3,190 112

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ronald Kurlander
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Ronald Kurlander were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Ronald Kurlander Psychiatry median Middle half National median
2019 $3,190 $184 $59–$605 $163
2020 $1,544 $119 $36–$372 $114
2021 $1,813 $143 $43–$576 $132
2022 $2,163 $153 $50–$590 $149
2023 $2,284 $170 $56–$651 $160
2024 $924 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Teva Pharmaceuticals USA, Inc. $1,980 61 payments
  2. Janssen Pharmaceuticals, Inc $1,386 43 payments
  3. Vanda Pharmaceuticals Inc. $1,363 51 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $885 38 payments
  5. Otsuka America Pharmaceutical, Inc. $846 28 payments
  6. Lundbeck LLC $727 43 payments
  7. Sunovion Pharmaceuticals Inc. $628 12 payments
  8. Alkermes, Inc. $493 16 payments
  9. AbbVie, Inc. $488 19 payments
  10. ITI, Inc. $431 6 payments
  11. Other $2,692 129 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $11,907 445 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2024
  1. AUSTEDO $1,758 59 payments
  2. SPRAVATO $1,372 42 payments
  3. FANAPT $1,363 51 payments
  4. HETLIOZ $1,102 48 payments
  5. REXULTI $846 28 payments
  6. TRINTELLIX $698 29 payments
  7. LATUDA $628 12 payments
  8. BRINTELLIX $555 34 payments
  9. LYBALVI $493 16 payments
  10. VRAYLAR $488 19 payments
  11. Other $6,120 251 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

1,250

Median for Psychiatry & Neurology: 100

Drug cost

$21,556

Median for Psychiatry & Neurology: $2,986

Branded share of claims

14.8%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trintellix Vortioxetine Hydrobromide Brand 13 $6,283
Vilazodone Hcl Generic 29 $1,983
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 54 $1,742
Aripiprazole Generic 24 $1,135
Buprenorphine Hcl Generic 54 $1,111
Clonazepam Generic 108 $923
Alprazolam Generic 212 $846
Methylphenidate Hcl Generic 23 $785
Bupropion Xl Bupropion Hcl Brand 47 $614
Quetiapine Fumarate Generic 59 $561

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FANAPT
  • Vanda Pharmaceuticals Inc. $319
$319 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $197
$197 — —
QUVIVIQ
  • IDORSIA PHARMACEUTICALS US INC $119
$119 — —
LYBALVI
  • Alkermes, Inc. $112
$112 — —
Adzenys XR-ODT
  • Neos Therapeutics, LP $65
$65 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

446 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record